Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches. (May 2021)

• Record Type: Journal Article
• Authors: Tahir ul Qamar, Muhammad; Ahmad, Sajjad; Fatima, Israr; Ahmad, Faisal; Shahid, Farah; Naz, Anam; Abbasi, Sumra Wajid; Khan, Abbas; Mirza, Muhammad Usman; Ashfaq, Usman Ali; Chen, Ling-Ling
• Is Part Of: Computers in biology and medicine. Volume 132(2021)
• Publication Date: 2021-05
• Subjects: Staphylococcus aureus -- Epitopes -- Vaccine -- Immunoinformatic -- MD simulations; Medicine -- Data processing -- Periodicals; Biology -- Data processing -- Periodicals; 610.285
• DOI: 10.1016/j.compbiomed.2021.104389
• Languages: English
• ISSNs: 0010-4825

Abstract

Abstract: Staphylococcus aureus is a deadly human bacterial pathogen that causes a wide variety of clinical manifestations. Invasive S. aureus infections in hospitals and the community are one of the main causes of mortality and morbidity, as virulent and multi-drug-resistant strains have evolved. There is an unmet and urgent clinical need for immune-based non-antibiotic approaches to treat these infections as the growing antibiotic resistance poses a significant public health danger. Subtractive proteomics assisted reverse vaccinology-based immunoinformatics pipeline was used in this study to target the suitable antigenic proteins for the development of multi-epitope vaccine (MEV). Three essential virulent and antigenic proteins were identified including Glycosyltransferase, Elastin Binding Protein, and Staphylococcal secretory antigen. A variety of immunoinformatics tools have been used to forecast T-cell and B-cell epitopes from target proteins. Seven CTL, five HTL, and eight LBL epitopes, connected through suitable linkers and adjuvant, were employed to design 444 amino acids long MEV construct. The vaccine was paired with the TLR4 agonist 50S ribosomal protein L7/L12 adjuvant to enhance the immune response towards the vaccine. The predicted MEV structure was assessed to be highly antigenic, non-toxic, non-allergenic, flexible, stable, and soluble. Molecular docking simulation of the MEV with the human TLR4 (toll-like receptor 4) and major histocompatibility complex molecules (MHCI and MHCII) was performed to validate the interactions with the receptors. Molecular dynamics (MD) simulation and MMGBSA binding free energy analyses were carried out for the stability evaluation and binding of the MEV docked complexes with TLR4, MHCI and MHCII. To achieve maximal vaccine protein expression with optimal post-translational modifications, MEV was reverse translated, its mRNA structure was analyzed, and finally in silico cloning was performed into E. coli expression host. These rigorous computational analyses supported the effectivity of proposed MEV in protection against infections associated with S. aureus. However, further experimental validations are required to fully evaluate the potential of proposed vaccine candidate. Highlights: Staphylococcus aureus has developed severe antibiotic resistance and no approved vaccine available yet. Multi-epitope vaccine developed using subtractive proteomics and reverse vaccinology approaches. Integrated pipeline based on immunoinformatics and bioinformatics tools validated vaccine efficiency. Designed vaccine showed stable binding with TLR4, MHCI and MHCII, and potential to induce host immune response.